Recursion Pharmaceuticals RXRX Q1 2026 Earnings Narrower Loss Surprises Market but Stock Dips on PreRevenue Status ATOS Q1 2026 Earnings Narrowing Loss Exceeds Expectations Amid Clinical Progress MS Q1 2026 Earnings Strong EPS Beat Drives Investor Optimism VEEV Q1 2026 Earnings EPS Surprises with 448 Beat Amid Modest Market Reaction MPLX Q1 2026 Earnings EPS Misses Estimates by 156 as Midstream Operations Face Headwinds DTG Q1 2026 Earnings EPS Miss Weighs on Investor Sentiment